Tag Archives: Harvard Business Review

Mallinckrodt will pay $100 million to settle drug antitrust (price-gouging) charges; why competition, not fines, is the only antidote

The News: Irish drugmaker Mallinckrodt PLC (Dublin) and a US subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for… Read more »

Novo Nordisk to cap price increases as drug costs face more scrutiny; do two drugmakers equal a trend?

With drug companies under fire over prices, the world’s largest insulin maker plans to limit increases and join competitors by introducing a model that ties the cost of medicines to… Read more »